Company: TELO
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-023970
Chunk: 1

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Item 1
Chunk 1
---
 2024 

    Three Months Ended June 30,  
    Six Months Ended June 30, 

    2025  
    2024  
    2025  
    2024 
  
    Revenues 
    $-  
    $-  

    Operating costs: 

    General and administrative expenses 
     5,027,071  
     879,695  
     6,877,857  
     1,621,237 
  
    Related party travel costs 
     -  
     -  
     -  
     370,500 
  
    Research and development expenses 
     42,839  
     594,801  
     379,835  
     1,398,824 
  
    Total operating costs 
     5,069,910  
     1,474,496  
     7,257,692  
     3,390,561 

    Interest income 
     1,362  
     25,493  
     9,362  
     25,493 
  
    Interest expense 
     (1,342) 
     -  
     (1,388) 
     (4,338,542)
  
    Net loss 
    $(5,069,890) 
    $(1,449,003) 
    $(7,249,718) 
    $(7,703,610)
  
    Basic and diluted net loss per share 
     (0.17) 
     (0.05) 
     (0.24) 
     (0.26)
  
    Basic and diluted weighted average common stock shares outstanding 
     30,010,165  
     29,609,814  
     30,265,285  
     29,443,148 

See
notes to condensed unaudited financial statements

4

TELOMIR
PHARMACEUTICALS, INC.

CONDENSED
STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)

FOR
THE THREE AND SIX MONTHS ENDED JUNE 30, 2025 AND 2024

(Unaudited)

    Shares  
    Amount  
    Capital  
     
    Deficit  
    (Deficit)